The DEAD box RNA helicase p68 (Ddx5) is an important androgen receptor (AR) transcriptional co-activator in prostate cancer (PCa) and is over-expressed in late stage disease. β-Catenin is a multifunctional protein with important structural and signalling functions which is up-regulated in PCa and similar to p68, interacts with the AR to co-activate expression of AR target genes. Importantly, p68 forms complexes with nuclear β-Catenin and promotes gene transcription in colon cancer indicating a functional interplay between these two proteins in cancer progression. In this study, we explore the relationship of p68 and β-Catenin in PCa to assess their potential co-operation in AR-dependent gene expression, which may be of importance in the development of castrate resistant prostate cancer (CRPCa). We use immunoprecipitation to demonstrate a novel interaction between p68 and β-Catenin in the nucleus of PCa cells, which is androgen dependent in LNCaP cells but androgen independent in a hormone refractory derivative of the same cell line (representative of the CRPCa disease type). Enhanced AR activity is seen in androgen-dependent luciferase reporter assays upon transient co-transfection of p68 and β-Catenin as an additive effect, and p68-depleted Chromatin-Immunoprecipitation (ChIP) showed a decrease in the recruitment of the AR and β-Catenin to androgen responsive promoter regions. In addition, we found p68 immunoprecipitated with the processive and non-processive form of RNA polymerase II (RNAP II) and show p68 recruited to elongating regions of the AR mediated PSA gene, suggesting a role for p68 in facilitating RNAP II transcription of AR mediated genes. These results suggest p68 is important in facilitating β-Catenin and AR transcriptional activity in PCa cells.
References
[1]
Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34–45.
[2]
Nieto M, Finn S, Loda M, Hahn WC (2007) Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 9: 1562–1568.
[3]
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33–39.
[4]
Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281: 22429–22433.
[5]
Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469–480.
[6]
Yardy GW, Brewster SF (2005) Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 8: 119–126.
[7]
Verras M, Sun Z (2006) Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett 237: 22–32.
[8]
Terry S, Yang X, Chen MW, Vacherot F, Buttyan R (2006) Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 99: 402–410.
[9]
Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC (2002) The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem 277: 17933–17943.
[10]
Wang G, Wang J, Sadar MD (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 68: 9918–9927.
[11]
Liu S, Vinall RL, Tepper C, Shi XB, Xue LR, et al. (2008) Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene 27: 499–505.
[12]
Schweizer L, Rizzo CA, Spires TE, Platero JS, Wu Q, et al. (2008) The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 9: 4.
[13]
Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, et al. (2007) Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res 67: 5747–5753.
[14]
Whitaker HC, Girling J, Warren AY, Leung H, Mills IG, et al. (2008) Alterations in beta-catenin expression and localization in prostate cancer. Prostate 68: 1196–1205.
[15]
Chesire DR, Ewing CM, Gage WR, Isaacs WB (2002) In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21: 2679–2694.
[16]
Janknecht R (2010) Multi-talented DEAD-box proteins and potential tumor promoters: p68 RNA helicase (DDX5) and its paralog, p72 RNA helicase (DDX17). Am J Transl Res 2: 223–234.
[17]
Fuller-Pace FV, Moore HC (2011) RNA helicases p68 and p72: multifunctional proteins with important implications for cancer development. Future Oncol 7: 239–251.
[18]
Saporita A, Chang HC, Winkeler C, Apicelli A, Kladney R, et al. (2011) RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis. Cancer Res 71: 6708–6717.
[19]
Fuller-Pace FV (2006) DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 34: 4206–4215.
[20]
Caretti G, Lei EP, Sartorelli V (2007) The DEAD-box p68/p72 proteins and the noncoding RNA steroid receptor activator SRA: eclectic regulators of disparate biological functions. Cell Cycle 6: 1172–1176.
[21]
Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, et al. (2008) The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res 68: 7938–7946.
[22]
Causevic M, Hislop RG, Kernohan NM, Carey FA, Kay RA, et al. (2001) Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours. Oncogene 20: 7734–7743.
[23]
Shin S, Rossow KL, Grande JP, Janknecht R (2007) Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Res 67: 7572–7578.
[24]
Yang L, Lin C, Zhao S, Wang H, Liu ZR (2007) Phosphorylation of p68 RNA Helicase Plays a Role in Platelet-derived Growth Factor-induced Cell Proliferation by Up-regulating Cyclin D1 and c-Myc Expression. J Biol Chem 282: 16811–16819.
[25]
Yang L, Lin C, Liu ZR (2006) P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127: 139–155.
[26]
Wang H, Gao X, Huang Y, Yang J, Liu ZR (2009) P68 RNA helicase is a nucleocytoplasmic shuttling protein. Cell Res 19: 1388–1400.
[27]
Stucke VM, Gorses D, Hofmann F (2008) DEAD-box RNA helicase p68 is not required for nuclear transloction of beta-catenin in colon cancer cells. Cell Cycle 7: 830–832.
[28]
Truica CI, Byers S, Gelmann EP (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709–4713.
[29]
Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 95: 1320–1326.
[30]
Clark EL, Fuller-Pace FV, Elliott DJ, Robson CN (2008) Coupling transcription to RNA processing via the p68 DEAD box RNA helicase androgen receptor co-activator in prostate cancer. Biochem Soc Trans 36: 546–547.
[31]
Gaughan L, Logan IR, Neal DE, Robson CN (2005) Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res 33: 13–26.
[32]
Li H, Kim JH, Koh SS, Stallcup MR (2004) Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways. J Biol Chem 279: 4212–4220.
[33]
Honig A, Auboeuf D, Parker MM, O'Malley BW, Berget SM (2002) Regulation of alternative splicing by the ATP-dependent DEAD-box RNA helicase p72. Mol Cell Biol 22: 5698–5707.
[34]
Brookes E, Pombo A (2009) Modifications of RNA polymerase II are pivotal in regulating gene expression states. EMBO Rep 10: 1213–1219.
[35]
Proudfoot NJ, Furger A, Dye MJ (2002) Integrating mRNA processing with transcription. Cell 108: 501–512.
[36]
Buszczak M, Spradling AC (2006) The Drosophila P68 RNA helicase regulates transcriptional deactivation by promoting RNA release from chromatin. Genes Dev 20: 977–989.
[37]
Germann S, Gratadou L, Zonta E, Dardenne E, Gaudineau B, et al.. (2012) Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor. Oncogene: 1–14.
[38]
Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, et al. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22: 2466–2477.
[39]
Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, et al. (1999) Tip60 is a nuclear hormone receptor coactivator. J Biol Chem 274: 17599–17604.
[40]
Jacobs AM, Nicol SM, Hislop RG, Jaffray EG, Hay RT, et al. (2007) SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene 40: 5866–5876.
[41]
Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, et al. (2009) The DEAD-box protein p72 regulates ERalpha？/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer. Oncogene 28: 4053–4064.
[42]
Gaughan L, Logan IR, Cook S, Neal DE, Robson CN (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem 277: 25904–25913.
[43]
Bates GJ, Nicol SM, Wilson BJ, Jacobs AM, Bourdon JC, et al. (2005) The DEAD box protein p68: a novel transcriptional coactivator of the p53 tumour suppressor. Embo J 24: 543–553.
[44]
Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, et al. (2006) Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol 26: 6502–6510.
[45]
Lee DY, Northrop JP, Kuo MH, Stallcup MR (2006) Histone H3 lysine 9 methyltransferase G9a is a transcriptional coactivator for nuclear receptors. J Biol Chem 281: 8476–8485.
